Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company dedicated to developing innovative combination therapies for patients battling complex cancers. In collaboration with Gilead Sciences, the company designs small molecules and antibody therapeutics targeting the adenosine pathway, TIGIT receptor, and HIF-2a transcription factors. Through rational biological combinations and precision clinical trial designs, Arcus Biosciences optimizes anti-tumor immune responses to improve patient survival outcomes.